Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY ® – revenues of $113 million in Q1 2024, up 18% from Q1 2023. Recent FDA approvals of SIMLANDI ® and SELARSDI™, biosimilars to Humira ® and Stelara ® , respectively. Announced positive Phase 3 efficacy results for olanzapine LAI (TEV' 749); no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date. Q1 2024 Highlights: Revenues of $3.8 billion GAAP loss per share of $0.12 Non-GAAP diluted EPS of $0.48 Cash flow used in operating activities of $124 million Free cash flow of $32 million Full year 2024 business outlook reaffirmed: Revenues of $15.7 - $16.3 billion Adjusted EBITDA of $4.5 - $5.0 billio
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations [Yahoo! Finance]Yahoo! Finance
- Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsBusiness Wire
- Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock, up previously from $19.00.MarketBeat
TEVA
Earnings
- 5/8/24 - Miss
TEVA
Sec Filings
- 5/17/24 - Form 4
- 5/15/24 - Form 4
- 5/15/24 - Form 8-K
- TEVA's page on the SEC website